renal cell carcinoma
Let an agent explain renal cell carcinoma and its subtypes, relay risk factors, diagnosis, staging and treatment from oncology guidelines in general terms, route people with symptoms or a diagnosis to clinicians, and distinguish renal cell carcinoma from urothelial carcinoma of the renal pelvis, Wilms tumour and benign kidney masses.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
Researched by: Claude
Bundle → Layer → Finding → Questions Filled
4 bundles · 8 layers · 8 findings · 16 questions
Understand What renal cell carcinoma is.
Definition
Definition and subtypes.
Definition
Definition.
- What is renal cell carcinoma, and how do clear cell, papillary, chromophobe and rare subtypes differ? definition
- Is the user asking about their own symptoms or diagnosis, which need a clinician? boundary
Causes
Risk factors and genetics.
Causes
Causes.
- What are the risk factors and hereditary syndromes, in general terms? provenance
- Which entry fits von Hippel-Lindau disease? action
Care Diagnosis and treatment.
Diagnosis
Diagnosis and staging.
Diagnosis
Diagnosis.
- How is renal cell carcinoma detected, imaged, biopsied and staged, as guidelines describe? provenance
- Which references are standard? provenance
Treatment
Treatment.
Treatment
Treatment.
- What treatments do guidelines recommend for localised and metastatic disease, in general terms? provenance
- Which sources are cited? provenance
Support Living with the disease.
Follow-up
Follow-up and survivorship.
Follow-up
Follow-up.
- What does follow-up after treatment involve, as guidelines state? provenance
- Which entry fits cancer survivorship? action
Organisations
Support organisations.
Organisations
Organisations.
- Where can patients find kidney cancer organisations and trials? action
- Which entry fits cancer support organisations? action
Context Research and epidemiology.
Research
Research.
Research
Research.
- What research directions exist in kidney cancer, with findings attributed? provenance
- Which entry fits cancer immunotherapy? action
Epidemiology
Epidemiology.
Epidemiology
Epidemiology.
- How common is renal cell carcinoma, and how do rates vary? provenance
- Which entry fits the epidemiology of cancer? action
Classifiers Filled
- Family
- Thing Registry
- Category
- Cross-cutting context
- Entry kind
- thing
- Plane
- XCT
- Domain
- XCT.STA
- Also called
- renal clear cell carcinoma, childhood kidney cell carcinoma, metastatic renal cell carcinoma, multilocular cystic clear cell renal cell carcinoma, hereditary conventional renal cell carcinoma, sporadic conventional renal cell carcinoma, Clear cell papillary renal cell carcinoma, hereditary renal cell carcinoma, Renal medullary carcinoma, granular renal cell carcinoma, Tubulocystic renal cell carcinoma, Thyroid-like follicular renal cell carcinoma
What it is Filled
The most common kidney cancer in adults, arising from the lining of the renal tubules, with clear cell carcinoma the main subtype alongside papillary, chromophobe and rarer forms such as multilocular cystic clear cell carcinoma, occurring sporadically or in hereditary syndromes such as von Hippel-Lindau disease, rarely in children, and staged from localised to metastatic; treatment ranges from surveillance and surgery to targeted and immune therapies, and anyone with blood in the urine, flank pain or a mass needs medical assessment.
Why it exists Filled
Let an agent explain renal cell carcinoma and its subtypes, relay risk factors, diagnosis, staging and treatment from oncology guidelines in general terms, route people with symptoms or a diagnosis to clinicians, and distinguish renal cell carcinoma from urothelial carcinoma of the renal pelvis, Wilms tumour and benign kidney masses.
Distinguishing features Filled
- Tubular epithelial origin
- Clear cell dominance
- VHL pathway
- Immunotherapy responsive
What robots and AI may and may not do Filled
Must not
- Diagnose or stage a person's kidney cancer.
- Recommend or discourage a specific treatment for a person.
- Present outdated treatment information as current.
- Disclose a person's diagnosis or genetic syndrome without consent.
Only with a human decision
- Any decision about testing, surgery or drug treatment.
May
- Describe renal cell carcinoma and its subtypes in general terms.
- Point people to clinicians, cancer services and patient organisations.
Moral aspects Filled
- Cancer patients are vulnerable to false hope and unproven treatments.
- Hereditary syndromes affect relatives who have not been tested.
Who is affected
- Patients
- Families with hereditary syndromes
- Clinicians
Owners Filled
Steward
The patient; clinicians and cancer registries hold the records.
Master systems
- Cancer registries
Links to other meta-models Filled
parent
- Q18556333 - registry parent class
related
- renal carcinoma - in registry terms
- von Hippel-Lindau disease - in hereditary cases
- Wilms tumour - a childhood kidney cancer
- immunotherapy - among other approaches
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.renal-cell-carcinoma
- Wikidata: Q1164529 (https://www.wikidata.org/wiki/Q1164529)
- ICD-10: C64 malignant neoplasm of kidney
- MeSH: D002292 Carcinoma, Renal Cell
Direct properties not applicable Not applicable
- share of kidney cancers in adults: about 90 percent
- clear cell share: about 75 percent
- new cases worldwide: about 430000 per year - kidney cancer, estimates
Plane XCT: no invented physical properties.
Recognition optional Filled
- Cancer of the renal tubular epithelium
- Clear cell, papillary, chromophobe, multilocular cystic, hereditary and sporadic, metastatic, childhood forms
- Urothelial carcinoma arises in the collecting system; Wilms tumour is a childhood embryonal tumour; oncocytoma is benign
- Not a visible object; a kidney mass on imaging.
Capabilities and actions required Filled
- explain subtypes
- relay diagnosis and treatment
- route to clinicians
- distinguish related tumours
Hazards and failure modes required Filled
- Agents giving personal medical advice
- Confusing subtypes and other kidney tumours
- Stale treatment information
Standards and interfaces required Filled
- ESMO, NCCN and EAU guidelines for kidney cancer
- Drug approvals for targeted and immune therapies
- Cancer registration rules
Context of use required Filled
- Not applicable; a disease.
- clear cell renal cell carcinoma
- papillary renal cell carcinoma
- chromophobe renal cell carcinoma
- multilocular cystic and other rare subtypes
- hereditary forms in VHL and other syndromes
- sporadic forms
- childhood renal cell carcinoma
- metastatic renal cell carcinoma
Sources Missing, in the backlog
Not described yet. This gap is in the card backlog.
Note: Written from model knowledge without web access; claims are unverified.
Open questions
- Should clear cell carcinoma and hereditary forms be separate primary entries?
- How should oncology guidelines be linked?
- The registry entry has merged aliases naming subtypes and settings; should they be split off?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q1164529/spec.json